{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.90","upperLimit":"128.00","value":"37.00"}]}],"title":"IL-8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"2800","value":"200"}]}],"title":"BDNF"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"2440.00","value":"99.00"}]}],"title":"IL-5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"149.00","value":"51.00"}]}],"title":"VEGF"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"368.00","upperLimit":"9780.00","value":"684.00"}]}],"title":"MCP-1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"218.00","value":"0.00"}]}],"title":"ITAC"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Serum levels were determined for 38 circulating proteins. Values showing statistically significant, ≥2-fold difference compared with baseline are reported here.","dispersionType":"Full Range","groups":[{"description":"Included all participants who received oral glasdegib in combination with cytarabine/daunorubicin in phase 1B portion.","id":"OG000","title":"Phase 1B: Glasdegib + Cytarabine/Daunorubicin"}],"paramType":"MEDIAN","populationDescription":"PD analysis set: all enrolled participants in the Phase 1B portion who received at least 1 dose of glasdegib, and had at least 1 PD parameter from the corresponding assay sample with a baseline and an adequate post treatment assessment.","reportingStatus":"POSTED","timeFrame":"Induction Cycle 1/Day 10, 1 Hour Post dose","title":"Serum Levels of Circulating Protein Analytes at Phase 1B - Induction Cycle 1/Day 10","type":"SECONDARY","unitOfMeasure":"pg/mL"}